Approval of inhaled insulin in Europe and United States

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7543.730-b (Published 23 March 2006) Cite this as: BMJ 2006;332:730
  1. Bruce Charlesworth, head of RMRS and medical affairs (bruce.charlesworth@pfizer.com)
  1. Pfizer Limited, Walton Oaks, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS

    EDITOR—We wish to respond to several points in the news item by Lenzer on the approval of inhaled insulin.1

    Firstly, the article states that critics say that Exubera fails to control postprandial glucose presentations as well as subcutaneous insulin. In fact, in clinical trials Exubera is comparable or superior to subcutaneous human insulin in terms of postprandial glucose control.24

    Secondly, the article raises concerns about the pulmonary effects of Exubera. Pfizer has …

    View Full Text

    Sign in

    Log in through your institution